Maraviroc modifies gut microbiota composition in a mouse model of obesity: A plausible therapeutic option to prevent metabolic disorders in hiv-infected patients;Maraviroc modifica la composición de la microbiota intestinal en un modelo animal de obesidad: Una posible opción terapéutica para prevenir los trastornos metabólicos en pacientes infectados por el VIH

Revista Espanola de Quimioterapia

Volumn 28, Issue 4, 2015, Pages 200-206

  Pérez Matute, Patricia ^a   Pérez Martínez, Laura ^a   Aguilera Lizarraga, Javier ^a   Blanco, José R ^a,b   Oteo, Jose A ^a,b  

^a CENTER FOR BIOMEDICAL RESEARCH OF LA RIOJA CIBIR   (Spain)

^b HOSPITAL SAN PEDRO   (Spain)

Author keywords

Feed Efficiency; Maraviroc; Metabolism; Microbiota; Obesity

Indexed keywords

ADIPOCYTOKINE; CHOLESTEROL; GLUCOSE; MARAVIROC; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CYCLOHEXANE DERIVATIVE; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTEROIDALES; BODY COMPOSITION; BODY WEIGHT; CALORIC INTAKE; CHOLESTEROL BLOOD LEVEL; CLOSTRIDIALES; CONTROLLED STUDY; DIGESTIVE TRACT PARAMETERS; ENTEROBACTERIALES; FATTY LIVER; FOOD INTAKE; GLUCOSE METABOLISM; GUT MICROBIOTA COMPOSITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INSULIN RESISTANCE; INTESTINE FLORA; LACTOBACILLALES; LIPID DIET; LIPID METABOLISM; MALE; MOUSE; MOUSE MODEL; NONHUMAN; OBESITY; REAL TIME POLYMERASE CHAIN REACTION; WEIGHT GAIN; ANIMAL; BACTERIAL TRANSLOCATION; BACTEROIDETES; C57BL MOUSE; CECUM; COMPLICATION; DRUG EFFECTS; FIRMICUTES; HIV INFECTIONS; ISOLATION AND PURIFICATION; METABOLIC DISEASES; METABOLISM; MICROBIOLOGY; MICROFLORA; NON-ALCOHOLIC FATTY LIVER DISEASE; PRECLINICAL STUDY; PROTEOBACTERIA; RANDOMIZATION; SPECIES DIFFERENCE;

ANIMALS; BACTERIAL TRANSLOCATION; BACTEROIDETES; CCR5 RECEPTOR ANTAGONISTS; CECUM; CYCLOHEXANES; DIET, HIGH-FAT; DRUG EVALUATION, PRECLINICAL; FIRMICUTES; HIV FUSION INHIBITORS; HIV INFECTIONS; HUMANS; INSULIN RESISTANCE; MALE; METABOLIC DISEASES; MICE; MICE, INBRED C57BL; MICROBIOTA; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; PROTEOBACTERIA; RANDOM ALLOCATION; SPECIES SPECIFICITY; TRIAZOLES; WEIGHT GAIN;

EID: 84942865329     PISSN: 02143429     EISSN: 19889518     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 2008;57:1470-81.
2. de La Serre CB, Ellis CL, Lee J, Hartman AL, Rutledge JC, Raybould HE. Propensity to high-fat diet-induced obesity in rats is associated with changes in the gut microbiota and gut inflammation. Am J Physiol Gastrointest Liver Physiol 2010;299:G440-8.
3. Spencer MD, Hamp TJ, Reid RW, Fischer LM, Zeisel SH, Fodor AA. Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency. Gastroenterology 2011;140:976-86.
4. Harris K, Kassis A, Major G, Chou CJ. Is the gut microbiota a new factor contributing to obesity and its metabolic disorders? J Obes 2012;2012:879151.
5. Parra J, Portilla J, Pulido F, Sanchez-de la Rosa R, Alonso-Villaverde C, Berenguer J, et al. Clinical utility of maraviroc. Clin Drug Investig 2011;31:527-42.
6. Diaz-Delfin J, Domingo P, Giralt M, Villarroya F. Maraviroc reduces cytokine expression and secretion in human adipose cells without altering adipogenic differentiation. Cytokine 2013;61:808-15.
7. Pérez-Matute P, Pérez-Martínez L, Rus A, Jareño M, Blanco JR, Oteo JA. Maraviroc shows differential effects on glucose uptake and lipolysis in human subcutaneous cultured adipocytes in comparison with omental adipocytes. 11th International Congress on Drug Therapy in HIV infection. Glasgow (UK), 2012.
8. Perez-Martinez L, Perez-Matute P, Aguilera-Lizarraga J, Rubio-Mediavilla S, Narro J, Recio E, et al. Maraviroc, a CCR5 antagonist, ameliorates the development of hepatic steatosis in a mouse model of non-alcoholic fatty liver disease (NAFLD). J Antimicrob Chemother 2014;69:1903-10.
9. Neff CP, Ndolo T, Tandon A, Habu Y, Akkina R. Oral pre-exposure prophylaxis by anti-retrovirals raltegravir and maraviroc protects against HIV-1 vaginal transmission in a humanized mouse model. PLoS One 2010;5:e15257.
10. Valdecantos MP, Perez-Matute P, Gonzalez-Muniesa P, Prieto-Hontoria PL, Moreno-Aliaga MJ, Martinez JA. Lipoic acid administration prevents nonalcoholic steatosis linked to long-term high-fat feeding by modulating mitochondrial function. J Nutr Biochem 2012;23:1676-84.
11. Ellis CL, Ma ZM, Mann SK, Li CS, Wu J, Knight TH, et al. Molecular characterization of stool microbiota in HIV-infected subjects by panbacterial and order-level 16S ribosomal DNA (rDNA) quantification and correlations with immune activation. J Acquir Immune Defic Syndr 2012;57:363-70.
12. Angelakis E, Armougom F, Million M, Raoult D. The relationship between gut microbiota and weight gain in humans. Future Microbiol 2012;7:91-109.
13. Backhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A 2004;101:15718-23.
14. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature 2006;444:1022-3.
15. Turnbaugh PJ, Backhed F, Fulton L, Gordon JI. Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host Microbe 2008;3:213-23.
16. Duncan SH, Lobley GE, Holtrop G, Ince J, Johnstone AM, Louis P, et al. Human colonic microbiota associated with diet, obesity and weight loss. Int J Obes (Lond) 2008;32:1720-4.
17. Million M, Angelakis E, Maraninchi M, Henry M, Giorgi R, Valero R, et al. Correlation between body mass index and gut concentrations of Lactobacillus reuteri, Bifidobacterium animalis, Methanobrevibacter smithii and Escherichia coli. Int J Obes (Lond) 2013;37:1460-6.
18. Zeng H, Liu J, Jackson MI, Zhao FQ, Yan L, Combs GF, Jr. Fatty liver accompanies an increase in lactobacillus species in the hind gut of C57BL/6 mice fed a high-fat diet. J Nutr 2013;143:627-31.
19. Vujkovic-Cvijin I, Dunham RM, Iwai S, Maher MC, Albright RG, Broadhurst MJ, et al. Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism. Sci Transl Med 2013;5:193ra91.
20. Ley RE, Backhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A 2005;102:11070-5.
21. Berraondo B, Marti A, Duncan JS, Trayhurn P, Martinez JA. Up-regulation of muscle UCP2 gene expression by a new beta3-adrenoceptor agonist, trecadrine, in obese (cafeteria) rodents, but down-regulation in lean animals. Int J Obes Relat Metab Disord 2000;24:156-63.
22. Perez-Matute P, Perez-Echarri N, Martinez JA, Marti A, Moreno-Aliaga MJ. Eicosapentaenoic acid actions on adiposity and insulin resistance in control and high-fat-fed rats: role of apoptosis, adiponectin and tumour necrosis factor-alpha. Br J Nutr 2007;97:389-98.
23. Gauffin Cano P, Santacruz A, Moya A, Sanz Y. Bacteroides uniformis CECT 7771 ameliorates metabolic and immunological dysfunction in mice with high-fat-diet induced obesity. PLoS One 2012;7:e41079.